Loading...
•
Dec 31, 2025
Ligand Q4 2025 Earnings Report
Ligand reported strong fourth quarter 2025 results with significant royalty-driven revenue growth and a return to GAAP profitability.
Key Takeaways
Ligand generated total revenues and income of 59666000 in Q4 2025, up 39% year-over-year, driven by a 45% increase in royalties, resulting in GAAP net income of 44784000 and adjusted net income of 42663000.
Total revenues and income increased 39% year-over-year to 59666000.
Royalty revenue grew 45% year-over-year to 50529000.
GAAP net income was 44784000 compared to a net loss in the prior year period.
Adjusted diluted EPS was 2.02 for the quarter.
Revenue by Segment
Forward Guidance
Ligand reaffirmed its 2026 financial guidance, expecting total revenue between 245000000 and 285000000 and adjusted earnings per diluted share of 8.00 to 9.00, supported by anticipated royalty and Captisol sales growth.
Positive Outlook
- Expected 2026 total revenue between 245000000 and 285000000.
- Projected 2026 royalty revenue between 200000000 and 225000000.
- Anticipated Captisol sales between 35000000 and 40000000.
- Adjusted EPS guidance of 8.00 to 9.00 for 2026.
- Strong balance sheet with 733521000 in cash and investments.
Challenges Ahead
- Revenue dependent on partner commercialization performance.
- Potential variability in Captisol material sales.
- Exposure to regulatory and clinical development risks from partners.
- Competition for royalty acquisition opportunities.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...